Author:
Spahn Muriel Aline,Luyten Kaat,Van Loy Tom,Sathekge Mike,Deroose Christophe M.,Koole Michel,Schols Dominique,Vanduffel Wim,De Vos Kristof,Annaert Pieter,Bormans Guy,Cleeren Frederik
Funder
Stichting Tegen Kanker
Fonds Wetenschappelijk Onderzoek
Reference48 articles.
1. The intricate role of CXCR4 in cancer;Chatterjee;Adv Cancer Res,2014
2. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent;Gourni;J Nucl Med,2011
3. First (18)F-labeled Pentixafor-based imaging agent for PET imaging of CXCR4 expression in vivo;Poschenrieder;Tomogr Ann Arbor Mich,2016
4. H. Hänscheid et al., “Biokinetics and Dosimetry of [ 177 Lu]Lu-Pentixather,” J Nucl Med, vol. 63, no. 5. pp. 754–760, 2022. doi:https://doi.org/10.2967/jnumed.121.262295.
5. First-in-human experience of CXCR4-directed Endoradiotherapy with 177Lu- and 90Y-labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease;Herrmann;J Nucl Med Off Publ Soc Nucl Med,2016